Trial Profile
A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors Genentech
- 24 Oct 2014 New trial record